An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2019
Price : $35 *
At a glance
- Drugs Cenegermin (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dompe Spa
- 25 Jun 2019 According to a Dompe Farmaceutici media release, this study was conducted at the General Hospital of Vienna (Austria)
- 25 Jun 2019 According to a Dompe Farmaceutici media release, results from this trial were published in the British Journal of Ophthalmology (BJO).
- 27 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.